Medicago’s plant-based COVID-19 vaccine shows positive Phase 2 results
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) have announced the positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago’s plant-derived COVID-19 vaccine candidate, which was tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and …